on Alamar Biosciences, Inc.
Alamar Biosciences Secures $50 Million Through Oversubscribed Financing and Expands Leadership
Alamar Biosciences, a leader in precision proteomics, announced the successful close of an oversubscribed convertible notes financing, raising over $50 million. New participants in this financing round include T. Rowe Price Investment Management and Braidwell LP. Existing investors such as Illumina Ventures and Sands Capital also contributed. This capital influx aims to enhance Alamar's precision proteomics platform, designed for early disease detection.
The company is reinforcing its leadership team with key appointments. Dr. Stephen Williams has joined as Chief Scientific Officer, bringing over 30 years of experience from roles at Standard BioTools, SomaLogic, and Pfizer. Additionally, Rebecca Chambers and Dr. Frank Witney have been appointed to the Board of Directors, offering substantial expertise in healthcare and life sciences.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Alamar Biosciences, Inc. news